Savara (NASDAQ:SVRA) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened

Savara Inc. (NASDAQ:SVRA) crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $4.98 and traded as high as $5.07. Savara shares last traded at $5.05, with a volume of 2,400,381 shares trading hands.

Analyst Upgrades and Downgrades

SVRA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. began coverage on shares of Savara in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target for the company. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a report on Wednesday, October 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.25.

Savara Stock Performance

The business has a 50-day moving average of $4.98 and a 200 day moving average of $5.36. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The company has a market cap of $1.04 billion, a PE ratio of -8.71 and a beta of 0.32.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities research analysts anticipate that Savara Inc. will post -0.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC lifted its stake in shares of Savara by 842.8% in the 3rd quarter. Sterling Capital Management LLC now owns 5,063 shares of the company’s stock worth $26,000 after purchasing an additional 4,526 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Savara during the third quarter valued at approximately $54,000. Principal Financial Group Inc. bought a new stake in Savara during the first quarter valued at approximately $57,000. Sequoia Financial Advisors LLC purchased a new stake in Savara during the second quarter valued at approximately $69,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Savara during the second quarter valued at approximately $77,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara’s lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.